According to the Zhitong Finance App, Hanson Pharmaceuticals (03692.HK) announced that HS-20118 tablets, a Class 1 new drug independently developed by the Group, have received a drug clinical trial approval notice issued by the China National Drug Administration (NMPA) to carry out clinical trials for moderate to severe plaque psoriasis.

According to the Zhitong Finance App, Hanson Pharmaceuticals (03692.HK) announced that HS-20118 tablets, a Class 1 new drug independently developed by the Group, have received a drug clinical trial approval notice issued by the China National Drug Administration (NMPA) to carry out clinical trials for moderate to severe plaque psoriasis.